NLRP2B and Ovarian Cancer

Recent genomic analyses of ovarian cancer have identified alterations in NLRP2B as part of a broader survey of copy number variations and epigenetic changes. In one study of 42 primary serous ovarian cancer samples with additional validation from TCGA cohorts (PMID:22174824), NLRP2B was included in a set of 346 genes demonstrating significant deletions or amplifications. A second independent study using SNP-based array analysis in an Italian ovarian cancer cohort further described a panel of candidate oncogenes and tumor suppressors, reinforcing the potential involvement of NLRP2B in ovarian cancer pathogenesis (PMID:33516089).

Despite its recurrent identification in large-scale genomic screens, detailed segregation data and precise variant-level evidence for NLRP2B are lacking. No specific point mutations or functional assays directly interrogating the gene’s role have been reported. Overall, the combined genetic and limited experimental evidence supports a limited gene–disease association for NLRP2B in ovarian cancer. Continued investigation is warranted to better define its mechanistic role and potential clinical utility in diagnostic decision-making.

References

• PloS ONE • 2011 • Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer PMID:22174824
• Translational Oncology • 2021 • Genome-wide analysis of copy number alterations led to the characterisation of PDCD10 as oncogene in ovarian cancer PMID:33516089

Evidence Based Scoring (AI generated)